![Mark G. Fromhold](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Mark G. Fromhold
Corporate Officer/Principal presso Koronis Pharmaceuticals, Inc.
Profilo
Mark G.
Fromhold is currently the VP-Manufacturing & Business Development at Koronis Pharmaceuticals, Inc. He previously worked as a Research Scientist at Chiron Corp.
and as a Senior CMC Project Manager at ICOS Corp.
Dr. Fromhold completed his undergraduate degree at Hope College and his graduate and doctorate degrees at Indiana University.
Posizioni attive di Mark G. Fromhold
Società | Posizione | Inizio |
---|---|---|
Koronis Pharmaceuticals, Inc.
![]() Koronis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Koronis Pharmaceuticals, Inc. develops antiviral therapeutics based on viral decay acceleration. Its therapeutics are designed to inhibit a specific viral protein or enzyme, drugs based on VDA are designed to provoke the rapid decay of the targeted virus by further increasing its naturally high rate of mutation. The company was founded by Richard Daifuku in 1998 and is headquartered in Seattle, WA. | Corporate Officer/Principal | 01/02/2011 |
Precedenti posizioni note di Mark G. Fromhold
Società | Posizione | Fine |
---|---|---|
Chiron Corp.
![]() Chiron Corp. Medical SpecialtiesHealth Technology Chiron Corp. provides nucleic acid test for blood screening. Its products include tigris system, target capture system, reagent preparation incubator, and many more. The company was founded in 1981 by William J. Rutter, Edward E. Penhoet & Pablo Valenzuela and is headquartered in Emeryville, CA. | Direttore Tecnico/Scientifico/R&S | - |
ICOS Corp.
![]() ICOS Corp. Pharmaceuticals: OtherHealth Technology ICOS Corp. manufactures medications to treat inflammation and other serious diseases. It focuses on the development of treatments for unmet medical conditions such as prostatic hyperplasia, hypertension, pulmonary arterial hypertension, cancer, and inflammatory diseases. The company was founded in 1989 by Christopher Henney and George Rathman and is headquartered in Bothell, WA. | Corporate Officer/Principal | - |
Formazione di Mark G. Fromhold
Indiana University | Doctorate Degree |
Hope College | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Aziende private | 3 |
---|---|
ICOS Corp.
![]() ICOS Corp. Pharmaceuticals: OtherHealth Technology ICOS Corp. manufactures medications to treat inflammation and other serious diseases. It focuses on the development of treatments for unmet medical conditions such as prostatic hyperplasia, hypertension, pulmonary arterial hypertension, cancer, and inflammatory diseases. The company was founded in 1989 by Christopher Henney and George Rathman and is headquartered in Bothell, WA. | Health Technology |
Chiron Corp.
![]() Chiron Corp. Medical SpecialtiesHealth Technology Chiron Corp. provides nucleic acid test for blood screening. Its products include tigris system, target capture system, reagent preparation incubator, and many more. The company was founded in 1981 by William J. Rutter, Edward E. Penhoet & Pablo Valenzuela and is headquartered in Emeryville, CA. | Health Technology |
Koronis Pharmaceuticals, Inc.
![]() Koronis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Koronis Pharmaceuticals, Inc. develops antiviral therapeutics based on viral decay acceleration. Its therapeutics are designed to inhibit a specific viral protein or enzyme, drugs based on VDA are designed to provoke the rapid decay of the targeted virus by further increasing its naturally high rate of mutation. The company was founded by Richard Daifuku in 1998 and is headquartered in Seattle, WA. | Health Technology |
- Borsa valori
- Insiders
- Mark G. Fromhold